Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

autologous anti-CD5 CAR T lymphocytes MB-105

A preparation of genetically modified autologous T cells expressing a chimeric antigen receptor (CAR) directed against cluster of differentiation 5 (CD5), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CD5 CAR T lymphocytes MB-105 target and bind to CD5-expressing tumor cells, thereby inducing selective cytotoxicity in CD5-expressing tumor cells. CD5 is a T-cell surface glycoprotein expressed on the surface of normal T cells and overexpressed on various B- and T-cell malignancies.
Synonym:autologous anti-CD5 CAR T cells MB-105
autologous anti-CD5 CAR-T cells MB-105
autologous CD5-specific CAR T cells MB-105
autologous CD5-targeted CAR-T cells MB-105
autologous CD5CAR-expressing T lymphocytes MB-105
Code name:MB 105
MB-105
MB105
Search NCI's Drug Dictionary